The advent of anti-TNF agents as the first approved targeted therapy in the treatment of
inflammatory bowel disease (IBD) patients has made a major impact on our existing …

The use of biologic agents, particularly anti-tumor necrosis factor (TNF)-α, has revolutionized
the treatment of inflammatory bowel diseases (IBD), modifying their natural history. Several …

The management of inflammatory bowel disease (IBD) has been transformed over the last
two decades by the arrival of tumor necrosis factor (TNF) antagonist agents. Recently …

Proposed treatment targets for the management of inflammatory bowel disease (IBD) have
moved beyond symptomatic improvement towards more objective end points, such as …

New targets in inflammatory bowel disease therapy: 2021 : Current Opinion in
Gastroenterology New targets in inflammatory bowel disease therapy: 2021 : Current …

Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat
inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal …

The treatment of IBD with anti-TNF agents has substantially evolved since their first
introduction more than a decade ago. The robust efficacy witnessed in many patients has …

Current available anti-inflammatory drugs, in particular monoclonal antibodies directed
against the cytokine tumor necrosis factor α (TNF), have greatly enhanced the treatment of …

Crohn's disease and ulcerative colitis are increasingly prevalent, relapsing and remitting
inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their …

Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn's disease―are
commonly treated with biologic drugs. However, only approximately two-thirds of patients …